Do analysts recommend QTRX or IBAC?

Quanterix currently has a consensus target price of $3.25, indicating a potential upside of 6.21%. Given Quanterix's stronger consensus rating and higher probable upside, research analysts plainly believe Quanterix is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quanterix 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 IB Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, QTRX or IBAC?

IB Acquisition has lower revenue, but higher earnings than Quanterix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quanterix $153.17M 0.94 -$107.15M -$2.63 N/A IB Acquisition N/A N/A N/A N/A N/A

Do analysts recommend IBAC or CDXS?

Codexis has a consensus price target of $6.50, indicating a potential upside of 403.88%. Given Codexis' stronger consensus rating and higher possible upside, analysts plainly believe Codexis is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IB Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Codexis 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has better earnings & valuation, IBAC or CDXS?

IB Acquisition has higher earnings, but lower revenue than Codexis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IB Acquisition N/A N/A N/A N/A N/A Codexis $70.39M 2.01 -$43.97M -$0.34 N/A

Do analysts recommend SEER or IBAC?

Seer presently has a consensus target price of $4.00, suggesting a potential upside of 92.31%. Given Seer's stronger consensus rating and higher probable upside, analysts plainly believe Seer is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seer 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 3.00 IB Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, SEER or IBAC?

IB Acquisition has lower revenue, but higher earnings than Seer. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Seer $16.58M 6.95 -$73.60M -$1.22 N/A IB Acquisition N/A N/A N/A N/A N/A

Is SEER or IBAC more profitable?

IB Acquisition has a net margin of 0.00% compared to Seer's net margin of -478.05%. IB Acquisition's return on equity of 0.00% beat Seer's return on equity. Company Net Margins Return on Equity Return on Assets Seer -478.05% -27.23% -23.99% IB Acquisition N/A N/A N/A

Do analysts recommend IBAC or MXCT?

MaxCyte has a consensus target price of $5.00, suggesting a potential upside of 300.00%. Given MaxCyte's stronger consensus rating and higher possible upside, analysts plainly believe MaxCyte is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IB Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MaxCyte 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, IBAC or MXCT?

IB Acquisition has higher earnings, but lower revenue than MaxCyte. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IB Acquisition N/A N/A N/A N/A N/A MaxCyte $33.03M 3.91 -$44.63M -$0.33 N/A

Do analysts recommend CSBR or IBAC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IB Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, CSBR or IBAC?

IB Acquisition has lower revenue, but higher earnings than Champions Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Champions Oncology $59.42M 1.13 -$1.17M -$0.08 N/A IB Acquisition N/A N/A N/A N/A N/A

IB Acquisition (IBAC) Competitors

$10.90 +0.05 (+0.41%)

As of 10:41 AM Eastern

Compare

IBAC vs. QTRX, CDXS, SEER, MXCT, and CSBR

Should you buy IB Acquisition stock or one of its competitors? IB Acquisition's main competitors and comparable companies include Quanterix (QTRX), Codexis (CDXS), Seer (SEER), MaxCyte (MXCT), and Champions Oncology (CSBR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does IB Acquisition compare to Quanterix?

Quanterix (NASDAQ:QTRX) and IB Acquisition (NASDAQ:IBAC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

In the previous week, Quanterix and Quanterix both had 2 articles in the media. Quanterix's average media sentiment score of 1.25 beat IB Acquisition's score of 0.39 indicating that Quanterix is being referred to more favorably in the media.

Company	Overall Sentiment
Quanterix	Positive
IB Acquisition	Neutral

Quanterix currently has a consensus target price of $3.25, indicating a potential upside of 6.21%. Given Quanterix's stronger consensus rating and higher probable upside, research analysts plainly believe Quanterix is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
IB Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

IB Acquisition has a net margin of 0.00% compared to Quanterix's net margin of -80.25%. IB Acquisition's return on equity of 0.00% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quanterix	-80.25%	-26.09%	-19.03%
IB Acquisition	N/A	N/A	N/A

IB Acquisition has lower revenue, but higher earnings than Quanterix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix	$153.17M	0.94	-$107.15M	-$2.63	N/A
IB Acquisition	N/A	N/A	N/A	N/A	N/A

86.5% of Quanterix shares are owned by institutional investors. 1.5% of Quanterix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Quanterix beats IB Acquisition on 6 of the 9 factors compared between the two stocks.

How does IB Acquisition compare to Codexis?

IB Acquisition (NASDAQ:IBAC) and Codexis (NASDAQ:CDXS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

78.5% of Codexis shares are held by institutional investors. 3.5% of Codexis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

IB Acquisition has a net margin of 0.00% compared to Codexis' net margin of -39.55%. IB Acquisition's return on equity of 0.00% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IB Acquisition	N/A	N/A	N/A
Codexis	-39.55%	-74.36%	-23.58%

Codexis has a consensus price target of $6.50, indicating a potential upside of 403.88%. Given Codexis' stronger consensus rating and higher possible upside, analysts plainly believe Codexis is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IB Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

IB Acquisition has higher earnings, but lower revenue than Codexis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IB Acquisition	N/A	N/A	N/A	N/A	N/A
Codexis	$70.39M	2.01	-$43.97M	-$0.34	N/A

In the previous week, Codexis had 1 more articles in the media than IB Acquisition. MarketBeat recorded 3 mentions for Codexis and 2 mentions for IB Acquisition. Codexis' average media sentiment score of 1.82 beat IB Acquisition's score of 0.39 indicating that Codexis is being referred to more favorably in the news media.

Company	Overall Sentiment
IB Acquisition	Neutral
Codexis	Very Positive

Summary

Codexis beats IB Acquisition on 8 of the 11 factors compared between the two stocks.

How does IB Acquisition compare to Seer?

Seer (NASDAQ:SEER) and IB Acquisition (NASDAQ:IBAC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

Seer presently has a consensus target price of $4.00, suggesting a potential upside of 92.31%. Given Seer's stronger consensus rating and higher probable upside, analysts plainly believe Seer is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
IB Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

IB Acquisition has lower revenue, but higher earnings than Seer.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$16.58M	6.95	-$73.60M	-$1.22	N/A
IB Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, IB Acquisition had 1 more articles in the media than Seer. MarketBeat recorded 2 mentions for IB Acquisition and 1 mentions for Seer. Seer's average media sentiment score of 1.82 beat IB Acquisition's score of 0.39 indicating that Seer is being referred to more favorably in the media.

Company	Overall Sentiment
Seer	Very Positive
IB Acquisition	Neutral

75.2% of Seer shares are held by institutional investors. 11.3% of Seer shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

IB Acquisition has a net margin of 0.00% compared to Seer's net margin of -478.05%. IB Acquisition's return on equity of 0.00% beat Seer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seer	-478.05%	-27.23%	-23.99%
IB Acquisition	N/A	N/A	N/A

Summary

Seer beats IB Acquisition on 7 of the 11 factors compared between the two stocks.

How does IB Acquisition compare to MaxCyte?

IB Acquisition (NASDAQ:IBAC) and MaxCyte (NASDAQ:MXCT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

68.8% of MaxCyte shares are held by institutional investors. 4.1% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, MaxCyte had 5 more articles in the media than IB Acquisition. MarketBeat recorded 7 mentions for MaxCyte and 2 mentions for IB Acquisition. MaxCyte's average media sentiment score of 0.64 beat IB Acquisition's score of 0.39 indicating that MaxCyte is being referred to more favorably in the news media.

Company	Overall Sentiment
IB Acquisition	Neutral
MaxCyte	Positive

IB Acquisition has a net margin of 0.00% compared to MaxCyte's net margin of -114.77%. IB Acquisition's return on equity of 0.00% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IB Acquisition	N/A	N/A	N/A
MaxCyte	-114.77%	-18.92%	-16.14%

MaxCyte has a consensus target price of $5.00, suggesting a potential upside of 300.00%. Given MaxCyte's stronger consensus rating and higher possible upside, analysts plainly believe MaxCyte is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IB Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IB Acquisition has higher earnings, but lower revenue than MaxCyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IB Acquisition	N/A	N/A	N/A	N/A	N/A
MaxCyte	$33.03M	3.91	-$44.63M	-$0.33	N/A

Summary

MaxCyte beats IB Acquisition on 8 of the 11 factors compared between the two stocks.

How does IB Acquisition compare to Champions Oncology?

Champions Oncology (NASDAQ:CSBR) and IB Acquisition (NASDAQ:IBAC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

In the previous week, Champions Oncology and Champions Oncology both had 2 articles in the media. Champions Oncology's average media sentiment score of 1.31 beat IB Acquisition's score of 0.39 indicating that Champions Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Champions Oncology	Positive
IB Acquisition	Neutral

IB Acquisition has a net margin of 0.00% compared to Champions Oncology's net margin of -1.82%. IB Acquisition's return on equity of 0.00% beat Champions Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-1.82%	-25.77%	-3.71%
IB Acquisition	N/A	N/A	N/A

41.3% of Champions Oncology shares are owned by institutional investors. 46.3% of Champions Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IB Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

IB Acquisition has lower revenue, but higher earnings than Champions Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$59.42M	1.13	-$1.17M	-$0.08	N/A
IB Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Champions Oncology beats IB Acquisition on 4 of the 7 factors compared between the two stocks.

Get IB Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IBAC vs. The Competition

Export

Metric	IB Acquisition	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$54.63M	$10.87B	$7.46B	$12.88B
Dividend Yield	N/A	1.45%	2.52%	19.59%
P/E Ratio	N/A	32.42	275.01	25.30
Price / Sales	N/A	105.06	572.88	75.05
Price / Cash	N/A	27.31	76.68	52.75
Price / Book	N/A	6.10	10.36	5.97
Net Income	N/A	$56.67B	$3.50B	$380.69M
7 Day Performance	-0.50%	-1.16%	-2.64%	-3.42%
1 Month Performance	-0.27%	4.17%	-6.91%	-5.96%
1 Year Performance	4.35%	21.87%	1.92%	-5.59%

IB Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IBAC IB Acquisition	N/A	$10.91 +0.4%	N/A	+4.5%	$54.63M	N/A	N/A	2
QTRX Quanterix	1.3948 of 5 stars	$3.28 +2.2%	$3.00 -8.5%	-47.8%	$151.81M	$138.90M	N/A	450	Analyst Forecast
CDXS Codexis	2.391 of 5 stars	$1.41 +3.7%	$6.50 +361.0%	-48.8%	$148.93M	$70.39M	N/A	146
SEER Seer	2.8995 of 5 stars	$2.19 +0.9%	$4.00 +82.6%	-5.9%	$120.16M	$16.58M	N/A	124
MXCT MaxCyte	3.5288 of 5 stars	$1.01 -1.0%	$5.00 +395.0%	-24.2%	$105.27M	$31.05M	N/A	91	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IBAC) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IB Acquisition (IBAC) Competitors

IBAC vs. QTRX, CDXS, SEER, MXCT, and CSBR

How does IB Acquisition compare to Quanterix?

Summary

How does IB Acquisition compare to Codexis?

Summary

How does IB Acquisition compare to Seer?

Summary

How does IB Acquisition compare to MaxCyte?

Summary

How does IB Acquisition compare to Champions Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBAC vs. The Competition

IB Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IB Acquisition (IBAC) Competitors

IBAC vs. QTRX, CDXS, SEER, MXCT, and CSBR

How does IB Acquisition compare to Quanterix?

Does the media refer more to QTRX or IBAC?

Do analysts recommend QTRX or IBAC?

Is QTRX or IBAC more profitable?

Which has higher earnings and valuation, QTRX or IBAC?

Do insiders & institutionals believe in QTRX or IBAC?

Summary

How does IB Acquisition compare to Codexis?

Do institutionals and insiders have more ownership in IBAC or CDXS?

Is IBAC or CDXS more profitable?

Do analysts recommend IBAC or CDXS?

Which has better earnings & valuation, IBAC or CDXS?

Does the media prefer IBAC or CDXS?

Summary

How does IB Acquisition compare to Seer?

Do analysts recommend SEER or IBAC?

Which has stronger earnings and valuation, SEER or IBAC?

Does the media prefer SEER or IBAC?

Do insiders and institutionals hold more shares of SEER or IBAC?

Is SEER or IBAC more profitable?

Summary

How does IB Acquisition compare to MaxCyte?

Do institutionals & insiders hold more shares of IBAC or MXCT?

Does the media prefer IBAC or MXCT?

Is IBAC or MXCT more profitable?

Do analysts recommend IBAC or MXCT?

Which has preferable earnings & valuation, IBAC or MXCT?

Summary

How does IB Acquisition compare to Champions Oncology?

Does the media favor CSBR or IBAC?

Is CSBR or IBAC more profitable?

Do insiders & institutionals believe in CSBR or IBAC?

Do analysts recommend CSBR or IBAC?

Which has higher valuation & earnings, CSBR or IBAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBAC vs. The Competition

IB Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools